sanofi2d
Zgłoszenie naruszenie prawa na podstawie lokalnej Procedury Zgłoszeń Wewnętrznych i Podejmowania Działań Następczych w Sanofi Sp. z o.o.
Niniejszym informujemy, że zgodnie z wymogami Ustawy z dnia 14 czerwca 2024 r. o ochronie sygnalistów, firma Sanofi Sp. z o.o. wdrożyła lokalną Procedurę Zgłoszeń Wewnętrznych i Podejmowania Działań ...
sanofi2d
Infolinia zgodności
www.speakup-sanofi.com Tel.: 00 800 111 3819 Tel. 00 800 141 0213 Infolinie w języku polskim ...
sanofi3d
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of Directors Paris, . Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, ...
sanofi5d
Sepsis à E. coli
Le sepsis est une condition potentiellement mortelle qui se produit lorsque le système immunitaire de l’organisme réagit de manière excessive à une infection. S’il n’est pas détecté et traité ...
sanofi5d
E. coli sepsis
Sepsis is a life-threatening condition that happens when the body’s immune system has an extreme response to an infection.
sanofi5d
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the ...
sanofi6d
Press Release: Availability of the Q4 2024 Aide-mémoire
Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: ...
sanofi6d
Communiqués de presse
Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées ...
sanofi10d
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...
sanofi12d
Mental Health in Multiple Sclerosis: An Unnerving Aspect of the Disease
Many symptoms of MS are visible to the outside world, such as movement or speech problems, but there are also invisible symptoms (unseen by others) that significantly impact the lives of those living ...
sanofi12d
Sclérose en plaques : l'impact sur la santé mentale
De nombreux symptômes de la sclérose en plaques (SEP) sont visibles, comme les problèmes de mouvement ou de parole, mais il existe aussi des symptômes invisibles qui impactent considérablement la vie ...